Edwards Lifesciences Corporation $EW Stake Decreased by Litman Gregory Wealth Management LLC

Litman Gregory Wealth Management LLC trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 8.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,127 shares of the medical research company’s stock after selling 11,665 shares during the quarter. Litman Gregory Wealth Management LLC’s holdings in Edwards Lifesciences were worth $10,353,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in EW. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock valued at $5,474,515,000 after acquiring an additional 798,801 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after purchasing an additional 45,555 shares during the period. Jennison Associates LLC raised its stake in shares of Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after purchasing an additional 1,584,958 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares in the last quarter. Finally, Norges Bank acquired a new stake in Edwards Lifesciences in the second quarter worth about $580,640,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 45,465 shares of company stock valued at $3,804,610. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

NYSE EW opened at $86.83 on Friday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The business’s fifty day moving average is $83.84 and its two-hundred day moving average is $79.58. The stock has a market capitalization of $50.39 billion, a P/E ratio of 37.43, a P/E/G ratio of 3.88 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company’s revenue was up 14.7% compared to the same quarter last year. During the same period last year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on EW shares. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Mizuho boosted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. UBS Group set a $92.00 target price on Edwards Lifesciences in a research report on Friday, December 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $93.95.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.